ADMA
NASDAQADMA Biologics Inc
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$7.97-8.58 (-51.83%)
2026-03-042026-06-05
News · 26 weeks49-78%
2025-12-142026-06-07
Mix2390d
- Insider8(35%)
- SEC Filings7(30%)
- Other4(17%)
- Analyst2(9%)
- Earnings2(9%)
Latest news
25 items- SECADMA Biologics Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- INSIDERDirector Grossman Jerrold B bought $50,624 worth of shares (6,400 units at $7.91), increasing direct ownership by 1% to 520,284 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERDirector Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 2% to 513,884 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERDirector Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 3% to 501,384 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECSEC Form 10-Q filed by ADMA Biologics Inc10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA(2) of $59.7 Million, Representing 24% Year-Over-Year Growth 1Q 2026 Cash from Operations of $58 Million Highlights Strong Cash Generation Strong Balance Sheet and Financial Flexibility Support Continued Execution Reiterates Confidence in ASCENIV Growth Outlook Driven by Durable Demand Fundamentals Updates FY 2026 Outlook and Withdraws Long-Term Guidance to Reflect Evolving U.S. Plasma Products and IG Market Competitive Dynamics RAMSEY, N.J. and
- SECADMA Biologics Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and OlderRAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the U.S. Food and Drug Administration ("FDA") has approved the Company's supplemental Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for ASCENIV™. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of ASCENIV's prescribing information t
- PRADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uniq
- ANALYSTCanaccord Genuity initiated coverage on ADMA Biologics with a new price targetCanaccord Genuity initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $21.00
- SECSEC Form DEFA14A filed by ADMA Biologics IncDEFA14A - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECSEC Form DEF 14A filed by ADMA Biologics IncDEF 14A - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- INSIDERSEC Form 4 filed by Kestenberg-Messina Kaitlin M.4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECADMA Biologics Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper ResearchShort seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines Highlights that Demand for – and Utilization of – ASCENIV Has Grown Steadily Over Past Two Years and is at Record High Details that Stocking Levels Maintained by ADMA's Distributors Align with Industry Standards and Reflect the Long Production Cycle for ASCENIV RAMSEY, N.J. and BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company ded
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ADMA Biologics IncSCHEDULE 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)
- ANALYSTADMA Biologics downgraded by Cantor FitzgeraldCantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral
- PRADMA Biologics Addresses Misleading Short-Seller ReportRAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a report issued on March 24, 2026 by Culper Research (the "Short Report"), a firm that has published similarly negative "research reports" regarding public companies after taking short positions in the stock. The Short Report discloses that Culper Research holds a short position in ADMA. ADMA, and its Board of Directors takes seriously its obligations to fairly and accurately report its operating and financial
- INSIDERDirector Guiheen Lawrence P. exercised 30,000 shares at a strike of $3.66, gifted 30,000 shares and received a gift of 30,000 shares (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $318,360 worth of shares (21,000 units at $15.16), decreasing direct ownership by 0.28% to 2,112,777 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERSEC Form 4 filed by ADMA Biologics Inc4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S covered exercise/tax liability with 85,951 shares, decreasing direct ownership by 4% to 2,118,777 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERDirector Elms Steve bought $217,420 worth of shares (14,000 units at $15.53) (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERPresident and CEO Grossman Adam S covered exercise/tax liability with 54,858 shares, decreasing direct ownership by 2% to 2,204,728 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
ADMA FAQ
6 questionsWhat does ADMA Biologics Inc do?
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including...Where does ADMA stock trade?
ADMA Biologics Inc (ADMA) is listed on NASDAQ.What sector and industry is ADMA in?
ADMA Biologics Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ADMA?
ADMA Biologics Inc has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $2100.00 price target on 2026-04-21. Recent price targets range from $450.00 to $2100.00.What companies are similar to ADMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ADMA side-by-side with any of them on Quantisnow.How can I track ADMA on Quantisnow?
Quantisnow aggregates ADMA Biologics Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADMA to receive live email and push alerts on every new disclosure.